- Home
- OVID vs CYCC Comparison
OVID vs CYCC Comparison
Compare OVID & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- CYCC
- Stock Information
- Founded
- OVID 2014
- CYCC 1992
- Country
- OVID United States
- CYCC Malaysia
- Employees
- OVID N/A
- CYCC N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- CYCC Health Care
- Exchange
- OVID Nasdaq
- CYCC Nasdaq
- Market Cap
- OVID 20.6M
- CYCC 17.5M
- IPO Year
- OVID 2017
- CYCC N/A
- Fundamental
- Price
- OVID $1.23
- CYCC $7.12
- Analyst Decision
- OVID Strong Buy
- CYCC
- Analyst Count
- OVID 4
- CYCC 0
- Target Price
- OVID $3.13
- CYCC N/A
- AVG Volume (30 Days)
- OVID 2.0M
- CYCC 86.9K
- Earning Date
- OVID 08-13-2025
- CYCC 08-13-2025
- Dividend Yield
- OVID N/A
- CYCC N/A
- EPS Growth
- OVID N/A
- CYCC N/A
- EPS
- OVID N/A
- CYCC N/A
- Revenue
- OVID $6,651,000.00
- CYCC $10,000.00
- Revenue This Year
- OVID $708.13
- CYCC $137.21
- Revenue Next Year
- OVID N/A
- CYCC N/A
- P/E Ratio
- OVID N/A
- CYCC N/A
- Revenue Growth
- OVID 1070.95
- CYCC N/A
- 52 Week Low
- OVID $0.24
- CYCC $3.08
- 52 Week High
- OVID $1.47
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- OVID 70.64
- CYCC 41.06
- Support Level
- OVID $1.16
- CYCC $7.30
- Resistance Level
- OVID $1.30
- CYCC $8.82
- Average True Range (ATR)
- OVID 0.11
- CYCC 0.63
- MACD
- OVID 0.01
- CYCC 0.03
- Stochastic Oscillator
- OVID 78.00
- CYCC 17.87
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.